Table 1.
Clinical demographics of the subjects.
| Discovery cohort (N = 127) | Validation cohort (N = 100) | |||||
|---|---|---|---|---|---|---|
| Racteristics | leukopenia N = 27 | Non-leukopenia N = 100 | p | leukopenia N = 26 | Non-leukopenia N = 74 | p |
| Gender, Male, n (%) | 15 (55.6) | 82 (82) | 0.004 | 15 (57.7) | 60 (81.1) | 0.018 |
| Age, n (%) | 0.30 | 0.37 | ||||
| < 18 | 1 (3.7) | 3 (3) | 1 (3.8) | 1 (1.4) | ||
| 18~40 | 22 (81.5) | 88 (88) | 19 (73.1) | 58 (78.4) | ||
| >40 | 4 (14.8) | 9 (9) | 6 (23.1) | 15 (20.2) | ||
| Diagnosis, n (%) | ||||||
| CD | 26 (96.3) | 99 (99) | 0.32 | 26 (100) | 73 (98.6) | 0.55 |
| UC | 1 (3.7) | 1 (1) | 0 (0) | 1 (1.4) | ||
| NUDT15 rs116855232, n (%) | ||||||
| CC | 19 (70.4) | 92 (92) | 0.003 | 19 (73.1) | 66 (89.2) | 0.048 |
| CT | 8 (29.6) | 8 (8) | 7 (26.9) | 8 (10.8) | ||
| Medication | ||||||
| AZA | 21 (77.8) | 91 (91) | 0.06 | 23 (88.5) | 71 (95.9) | 0.17 |
| 6-MP | 6 (22.2) | 9 (9) | 3 (11.5) | 3 (4.1) | ||
| Thiopurines dose, AZA mg/kg/day, median (IQR) | 1.2 (0.9–1.7) | 1.6 (1.1–1.9) | 1.5 (1.1–2.0) | 1.6 (1.11.9) | ||
| Co-medication | 0.052 | 0.27 | ||||
| Steroids, n (%) | 1 (3.7) | 13 (13) | 2 (7.7) | 6 (8.1) | ||
| Infliximab, n (%) | 3 (11.1) | 7 (7) | 6 (23.1) | 0 (0) | ||
| 5-aminosalicylic acid, n (%) | 1 (3.7) | 0 (0) | 0 (0) | 2 (2.7) | ||
| EEN, n (%) | 3 (11.1) | 3 (3) | 0 (0) | 0 | ||
AZA, azathioprine; CD, Crohn's disease; IBD, inflammatory bowel disease; IQR, interquartile range; OR, odds ratio; UC, ulcerative colitis; EEN, Exclusive Enteral Nutrition.